101 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
ARRY Array BioPharma Inc. $17.19 $3.57B Buy
Article Searches
Array BioPharma's (ARRY) CEO Ron Squarer on Q3 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3970785-array-biopharmas-arry-ceo-ron-squarer-q3-2016-results-earnings-call-transcript?source=feed_all_articles May 03, 2016 - Array BioPharma Inc. (NASDAQ:ARRY) Q3 2016 Earnings Conference Call May 3, 2016 AM ET Executives Tricia Haugeto - Director, Corporate Communications, IR Ron Squarer - CEO Dave Horin - CFO Victor Sando
Array BioPharma (ARRY) Q2 2016 Results - Earnings Call Webcast http://seekingalpha.com/article/3847556-array-biopharma-arry-q2-2016-results-earnings-call-webcast?source=feed_all_articles Feb 02, 2016 -
Screen: Stocks With Estimated Revenue Up 5% - January http://www.gurufocus.com/news/385252/screen-stocks-with-estimated-revenue-up-5--january- Jan 18, 2016 - Screen: Stocks With Estimated Revenue Up 5% - January, Stocks: MGLN,AGTC,PLAY,ARRY,SWHC,KIM,HZNP, release date:Jan 18, 2016
InsiderInsights.com Daily Round Up 1/11/16: APC, PSX, SRE, XLRN http://seekingalpha.com/article/3804186-insiderinsights-com-daily-round-up-1-11-16-apc-psx-sre-xlrn?source=feed_all_articles Jan 12, 2016 -
New Valuation Approach - PTR: PTR-Based Fund Delivers Over 63% Annual Returns In Big Data Simulations http://seekingalpha.com/article/3771096-new-valuation-approach-ptr-ptr-based-fund-delivers-over-63-percent-annual-returns-in-big-data-simulations?source=feed_all_articles Dec 22, 2015 -
Premarket Biotech Digest: Tracking Gilead HCV Sales, Shire-Baxalta Deal, AstraZeneca Deal http://seekingalpha.com/article/3762286-premarket-biotech-digest-tracking-gilead-hcv-sales-shire-baxalta-deal-astrazeneca-deal?source=feed_tag_editors_picks Dec 17, 2015 - Gilead HCV sales in the U.S. will see a slight slowdown but beat consensus forecast.WSJ says Shire’s pursuit of Baxalta in final stages.AstraZeneca acquires 55% stake in Acerta.
MyoKardia IPO: Early Stage, Skittish IPO Market Leave Us Hesitant http://seekingalpha.com/article/3606906-myokardia-ipo-early-stage-skittish-ipo-market-leave-us-hesitant?source=feed_tag_ipo_analysis Oct 27, 2015 - SF-based MYOK is a clinical-stage biopharmaceutical, developing therapies for rare and serious cardiovascular diseases. MYOK scheduled a ~$74 million NASDAQ IPO; lead underwriters Cowen & Credit Suiss
Premarket Biotech Digest: Pump And Dumps, MannKind DTC Campaign, Opdivo ODD http://seekingalpha.com/article/3478136-premarket-biotech-digest-pump-and-dumps-mannkind-dtc-campaign-opdivo-odd?source=feed_sector_healthcare Aug 31, 2015 - This article discusses stock promotions.
Sell SunEdison Into Strength - Cramer's Lightning Round (8/28/15) http://seekingalpha.com/article/3477646-sell-sunedison-into-strength-cramers-lightning-round-8-28-15?source=feed_tag_cramers_picks Aug 31, 2015 - Array Biopharma is a speculative buy.
Premarket Biotech Digest: Major Mayo Research, Axovant Still Shortable, Mylan Perrigo Bid http://seekingalpha.com/article/3467496-premarket-biotech-digest-major-mayo-research-axovant-still-shortable-mylan-perrigo-bid?source=feed_sector_healthcare Aug 26, 2015 - Major research at Mayo Clinic on converting cancer cells to normal cells.

Pages: 1...567891011

<<<Page 10